We previously showed that ZNF154 methylation detection in ovarian cancer plasma outperformed patient CA-125 measurement (69.6% vs. 47.8%, correct classification, respectively), and combined, the two markers showed improvement over ZNF154 alone (87.0%, correct classification) [22]. This evidence concerns the gene ZNF154 and ovarian cancer.